Clinical Trial: A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678957) titled 'A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer' on June 25.

Brief Summary: This trial is a randomized, open-label, multicenter Phase II study designed to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally recurrent or metastatic HR-positive, HER2-low expressing breast cancer.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG: DS-8201

Administration by intravenous infusion for a cycle of 3 we...